Terms: = Sarcomas AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1
33 results:
1. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Nelson BE; Saleem S; Damodaran S; Somaiah N; Piha-Paul S; Moore JA; Yilmaz B; Ogbonna D; Karp DD; Dumbrava E; Tsimberidou AM; Hong DS; Rodon Ahnert J; Milton DR; Zheng X; Booser DJ; Ibrahim NK; Conley AP; Bhosale P; Rojas Hernandez CM; Tripathy D; Naing A; Meric-Bernstam F
Cancer; 2023 Jul; 129(14):2201-2213. PubMed ID: 37016732
[TBL] [Abstract] [Full Text] [Related]
2. The efficacy of selinexor (KPT-330), an xpo1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract] [Full Text] [Related]
3. Nuclear RNA transcript levels modulate nucleocytoplasmic distribution of ALS/FTD-associated protein FUS.
Tsai YL; Mu YC; Manley JL
Sci Rep; 2022 May; 12(1):8180. PubMed ID: 35581240
[TBL] [Abstract] [Full Text] [Related]
4. Selinexor decreases HIF-1α via inhibition of crm1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
[TBL] [Abstract] [Full Text] [Related]
5. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
[TBL] [Abstract] [Full Text] [Related]
6. Targeting xpo1 enhances innate immune response and inhibits KSHV lytic replication during primary infection by nuclear stabilization of the p62 autophagy adaptor protein.
Meng W; Gao SJ
Cell Death Dis; 2021 Jan; 12(1):29. PubMed ID: 33414399
[TBL] [Abstract] [Full Text] [Related]
7. Circ-xpo1 upregulates xpo1 expression by sponging multiple miRNAs to facilitate osteosarcoma cell progression.
Jiang Y; Hou J; Zhang X; Xu G; Wang Y; Shen L; Wu Y; Li Y; Yao L
Exp Mol Pathol; 2020 Dec; 117():104553. PubMed ID: 33091396
[TBL] [Abstract] [Full Text] [Related]
8. Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Jeitany M; Prabhu A; Dakle P; Pathak E; Madan V; Kanojia D; Mukundan V; Jiang YY; Landesman Y; Tam WL; Kappei D; Koeffler HP
Cell Mol Life Sci; 2021 Feb; 78(4):1837-1851. PubMed ID: 32851475
[TBL] [Abstract] [Full Text] [Related]
9. CRISPR-Cas9 Screening of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Cells Identifies xpo1 as a Vulnerable Target of Cancer Cells.
Gruffaz M; Yuan H; Meng W; Liu H; Bae S; Kim JS; Lu C; Huang Y; Gao SJ
mBio; 2019 May; 10(3):. PubMed ID: 31088931
[TBL] [Abstract] [Full Text] [Related]
10. p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma.
Currier AW; Kolb EA; Gorlick RG; Roth ME; Gopalakrishnan V; Sampson VB
Sci Rep; 2019 Apr; 9(1):6161. PubMed ID: 30992462
[TBL] [Abstract] [Full Text] [Related]
11. FUS-induced neurotoxicity in Drosophila is prevented by downregulating nucleocytoplasmic transport proteins.
Steyaert J; Scheveneels W; Vanneste J; Van Damme P; Robberecht W; Callaerts P; Bogaert E; Van Den Bosch L
Hum Mol Genet; 2018 Dec; 27(23):4103-4116. PubMed ID: 30379317
[TBL] [Abstract] [Full Text] [Related]
12. In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals.
Widman DG; Gornisiewicz S; Shacham S; Tamir S
PLoS One; 2018; 13(10):e0200043. PubMed ID: 30332435
[TBL] [Abstract] [Full Text] [Related]
13. Therapeutic Effects of xpo1 Inhibition in Thymic Epithelial Tumors.
Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
[TBL] [Abstract] [Full Text] [Related]
14. Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
Nair JS; Musi E; Schwartz GK
Clin Cancer Res; 2017 Aug; 23(15):4301-4311. PubMed ID: 28314790
[No Abstract] [Full Text] [Related]
15. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract] [Full Text] [Related]
16. Integrated genetic and pharmacologic interrogation of rare cancers.
Hong AL; Tseng YY; Cowley GS; Jonas O; Cheah JH; Kynnap BD; Doshi MB; Oh C; Meyer SC; Church AJ; Gill S; Bielski CM; Keskula P; Imamovic A; Howell S; Kryukov GV; Clemons PA; Tsherniak A; Vazquez F; Crompton BD; Shamji AF; Rodriguez-Galindo C; Janeway KA; Roberts CW; Stegmaier K; van Hummelen P; Cima MJ; Langer RS; Garraway LA; Schreiber SL; Root DE; Hahn WC; Boehm JS
Nat Commun; 2016 Jun; 7():11987. PubMed ID: 27329820
[TBL] [Abstract] [Full Text] [Related]
17. crm1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
[TBL] [Abstract] [Full Text] [Related]
18. Preclinical activity of selinexor, an inhibitor of xpo1, in sarcoma.
Nakayama R; Zhang YX; Czaplinski JT; Anatone AJ; Sicinska ET; Fletcher JA; Demetri GD; Wagner AJ
Oncotarget; 2016 Mar; 7(13):16581-92. PubMed ID: 26918731
[TBL] [Abstract] [Full Text] [Related]
19. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
[TBL] [Abstract] [Full Text] [Related]
20. NC-mediated nucleolar localization of retroviral gag proteins.
Lochmann TL; Bann DV; Ryan EP; Beyer AR; Mao A; Cochrane A; Parent LJ
Virus Res; 2013 Feb; 171(2):304-18. PubMed ID: 23036987
[TBL] [Abstract] [Full Text] [Related]
[Next]